Prognostic and therapeutic significance of myeloma genetics and gene expression profiling

A. Keith Stewart, Rafael Fonseca

Research output: Contribution to journalReview articlepeer-review

107 Scopus citations


Molecular diagnostic tools and novel therapeutics now offer the potential for accurate prognostic and personalized treatment road maps for patients with multiple myeloma (MM). We will review the evidence and provide specific recommendations for routine clinical molecular genetic testing and use of such information to guide therapeutic decision making. In particular, the negative prognostic impact of specific IgH translocations such as the t(4;14), t(14;16), chromosome 13 deletion by conventional cytogenetics and loss of 17p13 by interphase fluorescence in situ hybridization are now established. Preliminary gene expression profiling studies have also demonstrated that individual genes (CSK1-B) or groups of genes can define prognosis with greater accuracy than conventional genetic markers and can provide pharmacogenomic and biologic insight into the pathophysiology, therapeutics, and future targets of myeloma. Importantly, we recommend that all clinical trials now adopt routine genetic testing and risk stratification.

Original languageEnglish (US)
Pages (from-to)6339-6344
Number of pages6
JournalJournal of Clinical Oncology
Issue number26
StatePublished - Dec 1 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prognostic and therapeutic significance of myeloma genetics and gene expression profiling'. Together they form a unique fingerprint.

Cite this